RxSight (RXST) Set to Post Earnings on Tuesday

RxSight (NASDAQ:RXST) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $27.19 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

RxSight (NASDAQ:RXST) last released its earnings results on Wednesday, August 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $33.74 million during the quarter, compared to analyst estimates of $32.55 million. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. On average, analysts expect RxSight to post ($1.03) EPS for the current fiscal year and ($1.22) EPS for the next fiscal year.

RxSight Stock Performance

Shares of NASDAQ:RXST opened at $4.93 on Tuesday. The company has a market cap of $205.04 million, a P/E ratio of -4.36 and a beta of 1.15. The stock’s 50-day moving average is $5.50 and its 200-day moving average is $6.48. RxSight has a 52-week low of $4.40 and a 52-week high of $13.22.

Analysts Set New Price Targets

Several analysts recently weighed in on RXST shares. UBS Group increased their target price on RxSight from $5.50 to $6.30 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded RxSight from a “hold” rating to a “sell” rating in a research report on Sunday. Jefferies Financial Group cut their price target on RxSight from $6.50 to $5.75 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of RxSight in a research report on Tuesday, July 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of RxSight in a research report on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, RxSight has an average rating of “Reduce” and an average target price of $8.17.

Insider Activity

In other RxSight news, CFO Mark Wilterding sold 7,765 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $54,044.40. Following the completion of the transaction, the chief financial officer owned 25,049 shares of the company’s stock, valued at $174,341.04. This represents a 23.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ronald M. Md Kurtz sold 5,100 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total value of $35,496.00. Following the completion of the sale, the insider owned 71,775 shares of the company’s stock, valued at $499,554. This represents a 6.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 16,947 shares of company stock valued at $117,951. 10.05% of the stock is owned by corporate insiders.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to customize a patient’s vision after surgery.

Its primary product is the RxSight Light Adjustable Lens, an intraocular lens implanted during cataract surgery. After implantation, the lens can be adjusted using ultraviolet light treatments delivered by the company’s Light Delivery Device, enabling physicians to refine the lens power based on the patient’s postoperative visual needs.